secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001213900-25-112728
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vyome reports Q3 cash $5.7M; VT-1953 Phase 2 interim hits primary endpoint
--------------------------------------------------------------------------

- VT-1953 Phase 2 interim data: statistically significant malodor reduction (p<0.001); pain and QoL improved; safety profile excellent.
- Cash, equivalents & short-term investments $5.7 million; expected runway through end of 2026 inclusive of clinical trials.
- Net loss primarily from one-time merger/financing non-cash charges; company is pre-revenue clinical stage.
- Clean capital structure: 5,556,295 shares outstanding, no preferred stock, no warrants or convertible notes.
- Acquired MIT startup Oculo to launch AI strategy; hired new CTO and SVP of Clinical Development with Big Pharma backgrounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000121390025112728/0001213900-25-112728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000121390025112728/ea0266347-8k_vyome.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-112728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer